We are live on
!
Find out more
PC
Polar Capital Portfolio holdings
AUM
$13.5B
1-Year Est. Return
55.9%
This Fund
S&P 500
This Quarter
Est. Return
+2.63%
1 Year Est. Return
+55.9%
3 Year Est. Return
+127.44%
5 Year Est. Return
+269.08%
10 Year Est. Return
–
AUM
$5.2B
AUM Growth
-$91.8M
(-1.7%)
Cap. Flow
-$238M
Cap. Flow
% of AUM
-4.58%
Top 10 Holdings %
Top 10 Hldgs %
22.29%
Holding
328
New
43
Increased
93
Reduced
100
Closed
61
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Stryker
SYK
|
+$38.2M |
| 2 |
Carnival Corporation Ltd
CCL
|
+$37.7M |
| 3 |
WBA
Walgreens Boots Alliance
WBA
|
+$35.3M |
| 4 |
Icon
ICLR
|
+$30.9M |
| 5 |
CELG
Celgene Corp
CELG
|
+$29.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$63.8M |
| 2 |
Danaher
DHR
|
+$50.4M |
| 3 |
AutoZone
AZO
|
+$36.8M |
| 4 |
AGN
Allergan plc
AGN
|
+$33.9M |
| 5 |
Biogen
BIIB
|
+$33.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.03% |
| 2 | Healthcare | 24.38% |
| 3 | Financials | 20.66% |
| 4 | Communication Services | 10.61% |
| 5 | Consumer Discretionary | 5.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Prosperity Bancshares
PB
$8.69B
| $478K | 0.01% |
8,272
+2,067
| +33% | +$112K |
|
252
Alkermes
ALKS
$8.79B
| $477K | 0.01% |
7,410
+3,372
| +84% | +$206K |
|
|
SIVB
253
DELISTED
SVB Financial Group
SIVB
| $458K | 0.01% |
3,184
-1,142
| -26% | -$154K |
|
|
QIWI
254
DELISTED
QIWI PLC
QIWI
| $438K | 0.01% |
15,617
+4,445
| +40% | +$126K |
|
|
SGMO
255
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $401K | 0.01% |
36,159
+1,833
| +5% | +$23.6K |
|
|
KYNB
256
Kyntra Bio
KYNB
$28.5M
| $383K | 0.01% |
651
+319
| +96% | +$186K |
|
257
Rocket Pharmaceuticals
RCKT
$355M
| $343K | 0.01% |
+17,500
| New | +$387K |
|
|
CMRX
258
DELISTED
Chimerix, Inc.
CMRX
| $329K | 0.01% |
7,132
-6,717
| -49% | -$269K |
|
259
WisdomTree
WT
$3.01B
| $328K | 0.01% |
14,950
-67,750
| -82% | -$1.43M |
|
|
CEMP
260
DELISTED
Cempra, Inc.
CEMP
| $321K | 0.01% |
+9,341
| New | +$330K |
|
|
VTAE
261
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
| $320K | 0.01% |
22,238
| – | – |
|
|
BLCM
262
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $235K | ﹤0.01% |
+1,105
| New | +$271K |
|
263
Fortinet
FTNT
$112B
| $204K | ﹤0.01% |
24,640
-384,695
| -94% | -$2.99M |
|
264
Daktronics
DAKT
$956M
| $138K | ﹤0.01% |
+11,600
| New | +$128K |
|
265
Agilent Technologies
A
$38.9B
| – | – |
-30,000
| Closed | -$1.25M |
|
266
American Airlines Group
AAL
$9.9B
| – | – |
-231,392
| Closed | -$12.2M |
|
267
Autodesk
ADSK
$47.7B
| – | – |
-78,761
| Closed | -$4.62M |
|
268
Alnylam Pharmaceuticals
ALNY
$37.2B
| – | – |
-6,857
| Closed | -$716K |
|
269
Applied Materials
AMAT
$410B
| – | – |
-517,928
| Closed | -$11.7M |
|
|
270
AutoZone
AZO
$50.2B
| – | – |
-53,959
| Closed | -$36.8M |
|
271
Baxter International
BAX
$12.1B
| – | – |
-46,025
| Closed | -$1.71M |
|
272
Bausch Health
BHC
$1.67B
| – | – |
-118,350
| Closed | -$23.5M |
|
|
CARM
273
DELISTED
Carisma Therapeutics
CARM
| – | – |
-1,402
| Closed | -$250K |
|
274
Celldex Therapeutics
CLDX
$2.8B
| – | – |
-1,304
| Closed | -$545K |
|
|
275
Danaher
DHR
$138B
| – | – |
-884,015
| Closed | -$50.4M |
|
Similar funds
ECM
FAAS
WAM
FS
NIMC
TI
VIM
PS
Polar Capital's Q2 2015 Portfolio in Review
As of Q2 2015, Polar Capital held 328 positions worth $5.2B, down 1.7% from $5.29B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Polar Capital withdrew a net $238M in Q2 2015, closing 61 positions and reducing 100 holdings. Its most notable exit was Danaher, an estimated $50.4M position sold in full.
By sector, the portfolio is most concentrated in Technology at 25% of assets, down from 26% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Polar Capital opened a new position in Stryker worth $38.5M.
- Polar Capital's largest Q2 2015 buy was Stryker: 402,973 shares worth $38.5M.
- Polar Capital added most to Celgene Corp in Q2 2015, an estimated $29.8M increase.
- Polar Capital's biggest Q2 2015 reduction was Merck, cutting an estimated $63.8M.
- Polar Capital fully exited Danaher in Q2 2015, selling an estimated $50.4M.
- Polar Capital's ten largest holdings make up 22% of its $5.2B portfolio in Q2 2015.
- Polar Capital opened 43 new positions and closed 61 in Q2 2015.
- Polar Capital's portfolio value fell 1.7% quarter-over-quarter to $5.2B.
Based on Polar Capital's 13F filing for Q2 2015, filed 14 Aug 2015.